Reeling from the deaths of two patients who took Duchenne muscular dystrophy gene therapy Elevidys, Sarepta is launching a ...

Dyne Therapeutics stock crashed Tuesday after several key executives departed on the heels of what the company calls "unprecedented" in DMD.

On March 16, 2023, Sarepta issued a press release announcing that “at its late cycle meeting for the SRP-9001 (delandistrogene moxeparvovec) biologics license application (BLA), the U.S. Food ...

Here are the five things you need to know, including the latest on Sarepta, possible changes at the FDA, real estate disputes, and the best time to be a soccer fan.

CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today its board of directors ...

Sarepta Therapeutics Announces Leadership Change and Equity Deal November 26, 2024 — 07:48 am EST Written by TipRanks Auto-Generated Newsdesk for TipRanks -> ...

The news triggered a 21% drop in Sarepta’s share price in after-hours trading, sinking the stock to $118 per share, even as Ingram sought to frame the change as a surprise rather than a setback.